Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SlovakiaBack to Slovakia

Clinical trials in Malacky

19 clinical trials in Malacky, Slovakia across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SlovakiaOur site in SlovakiaKlinickeSkusky.sk(opens in a new tab)
Malacky at a glance
19
clinical trials
  • Paediatric trials0
  • Research sites1
Type of trial
Recruitment status
Quick filters

19 trials in Malacky

Open in trial search

Arteriosclerosis

Recruiting

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Laroprovstat
  • Sponsor:AstraZeneca AB

Study on Baxdrostat and Dapagliflozin for Preventing Heart Failure in Patients at High Risk

Recruiting
Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Obesity+1

Recruiting

A study to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight and type 2 diabetes

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:LY3841136 sodium
  • Sponsor:Eli Lilly & Co.

Study on the Effects of Finerenone in Patients with Heart Failure and Preserved Ejection Fraction Hospitalized for Acute Decompensated Heart Failure

Recruiting
Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone
  • Sponsor:Colorado Prevention Center

Arteriosclerosis

Not yet recruiting

A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Sponsor:Eli Lilly & Co.

Type 2 diabetes mellitus

Not yet recruiting

A study to evaluate the effectiveness of NNC0662-0419 and semaglutide in people with type 2 diabetes

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years · Healthy volunteers
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Cardiac failure

Not recruiting

A study comparing ziltivekimab to placebo in patients with heart failure with mildly reduced or preserved ejection fraction and inflammation

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Hypercholesterolaemia

Not recruiting

Study of AZD0780 in patients with high cholesterol and heart disease or risk of heart disease to lower bad cholesterol levels

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Laroprovstat
  • Sponsor:AstraZeneca AB

Arteriosclerosis

Not recruiting

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Arteriosclerosis

Not recruiting

Study on Inclisiran for Preventing Heart Disease in High-Risk Patients

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG

Type 2 diabetes mellitus

Not recruiting

Evaluation of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Type 2 Diabetes Patients with High Cardiovascular Risk

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Dulaglutide
  • Sponsor:Eli Lilly & Co.

Type 2 diabetes mellitus

Not recruiting

A study to evaluate the effects of obicetrapib and ezetimibe on cholesterol levels in adults with type 2 diabetes or metabolic syndrome

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Ezetimibe
  • Sponsor:NewAmsterdam Pharma B.V.

Other cities in Slovakia

The busiest research cities in the country

All 92 cities in Slovakia

Clinical research in Malacky

What the registry says about research in the country

01 Cardiovascular Research

Groundbreaking studies focusing on heart failure prevention and innovative treatments for cardiovascular diseases. Research includes evaluation of combination therapies and novel compounds for reducing cardiac events.

  • Heart Failure Prevention
  • Cardiovascular Risk Management
  • Atherosclerotic Disease Prevention

Multiple trials are exploring preventive strategies and therapeutic interventions for heart-related conditions.

02 Metabolic Disorders

Comprehensive research into Type 2 Diabetes management and treatment, with particular focus on its relationship with obesity and cardiovascular outcomes.

  • Diabetes Management
  • Obesity Treatment
  • Metabolic Health

Studies are evaluating new therapeutic approaches for managing multiple metabolic conditions simultaneously.

03 Respiratory and Infectious Diseases

Important clinical investigations of treatments for community-acquired pneumonia and COVID-19, testing novel therapeutic approaches for better patient outcomes.

  • COVID-19 Treatment
  • Pneumonia Management
  • Respiratory Care

Research focuses on developing effective treatments for both viral and bacterial respiratory infections.

04 Vascular Medicine

Innovative research examining treatments for deep vein thrombosis, with emphasis on clot dissolution and patient safety in vascular conditions.

  • Thrombosis Treatment
  • Vascular Health
  • Blood Clot Management

Studies aim to advance therapeutic options for patients with serious vascular conditions.

Back to SlovakiaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.